Skip to main content
Macular Disease Foundation Australia
  • My Cart
  • Text Only
  • Listen
  • Print Page
  • Language
    • English
    • Arabic
    • Chinese
    • Greek
    • Italian
    • Portuguese
    • Spanish
    • Vietnamese
  • Search form

Check My Macula Check My Macula Join the Community Join the Community Order Free Information Order Free Information Call our helpline at 1800111709 Helpline
1800 111 709
Donate Donate
  • Home
  • Macular Disease
    • Macular Degeneration
      • About Macular Degeneration
      • What Happens?
      • Risk Factors
      • Prevention
      • Detection
      • Diagnosis
      • Treatment
      • Charles Bonnet Syndrome
      • Cataracts and Macular Degeneration
      • Frequently Asked Questions
      • How The Eye Works
    • Diabetic Retinopathy
      • About Diabetic Retinopathy
      • About Diabetes
      • What Happens?
      • Risk Factors
      • Prevention
      • Detection
      • Diagnosis
      • Treatment
      • Frequently Asked Questions
    • Low Vision
      • Living with Low Vision
      • Carer and Family
      • Aids and Technology
      • Slips, Trips and Falls
      • Legal blindness
    • Other Macular Diseases
      • Best Disease
      • Macular Hole
      • Macular Pucker
      • Macular Telangiectasia
      • Myopic Macular Degeneration
      • Retinal Detachment
      • Retinitis Pigmentosa
      • Retinal Vein Occlusion
      • Stargardt Disease
      • Central Serous Chorioretinopathy (CSC)
      • Vitreomacular Traction Syndrome
    • Visit Eye Health Professional
      • Eye Injection Costs and Rebates
    • Macular Disease
      • Anti-VEGF injections for macular disease
  • Research
    • Research Grants Program
      • Research Grants Awarded
      • Research Grant Recipients
      • Apply for the 2021 MDFA Research Grants Program
      • Research Grants panel
    • Support Research
    • Understanding Research
    • Latest Research
      • Research News
      • MDFA Research
      • Macular Diseases
      • Social Impact
    • Research Updates
      • Annual Research Update
      • Weekly Research Updates for Professionals
    • Research studies
  • Resources
    • Macula Month 2020
      • Order Macula Month resources
    • Order Publications and Resources
    • Find a Healthcare Provider
    • Audio and Video
      • Audio
      • See My World podcast
      • Patient Voices
      • Videos
    • Aged care resources
  • News & Events
    • Newsletters
      • Vision Voice Newsletters
      • Subscribe to Newsletters
      • Archive
    • News
      • 2020 news
      • 2019 News
      • 2018 News
      • 2017 News
      • 2016 News
      • Archived News
    • Events & Activities
      • Community Events
      • Education Sessions
      • Events Calendar
    • Media Centre
      • Media Releases
  • Foundation
    • Organisation
      • History
      • Objectives
      • Guiding Principles
      • Annual Reports
      • Whistleblower Policy
      • Financial Statements
    • People
      • Patron
      • State Patrons / Representatives
      • Ambassadors
      • Foundation Board
      • Committees
      • State Chairs
      • National Research Advisor
    • Our Work
      • Awareness
      • Education
      • Support Services
      • Research
      • Representation
    • Support Us
      • Donate
      • Bequests
      • Fundraise
      • Volunteer
      • Friends of the Foundation
      • Sponsors and Supporters
      • Professional Friends
    • Contact Us
Listen
Macular Disease Foundation Australia
Check My Macula Macula Join the Community Join Us Order Free Information Free Info Donate Donate
Menu
  • My Cart
    • Language
      • English
      • Arabic
      • Chinese
      • Greek
      • Italian
      • Portuguese
      • Spanish
      • Vietnamese
    • Home
    • Macular Disease
      • Macular Degeneration
        • About Macular Degeneration
        • What Happens?
        • Risk Factors
        • Prevention
        • Detection
        • Diagnosis
        • Treatment
        • Charles Bonnet Syndrome
        • Cataracts and Macular Degeneration
        • Frequently Asked Questions
        • How The Eye Works
      • Diabetic Retinopathy
        • About Diabetic Retinopathy
        • About Diabetes
        • What Happens?
        • Risk Factors
        • Prevention
        • Detection
        • Diagnosis
        • Treatment
        • Frequently Asked Questions
      • Low Vision
        • Living with Low Vision
        • Carer and Family
        • Aids and Technology
        • Slips, Trips and Falls
        • Legal blindness
      • Other Macular Diseases
        • Best Disease
        • Macular Hole
        • Macular Pucker
        • Macular Telangiectasia
        • Myopic Macular Degeneration
        • Retinal Detachment
        • Retinitis Pigmentosa
        • Retinal Vein Occlusion
        • Stargardt Disease
        • Central Serous Chorioretinopathy (CSC)
        • Vitreomacular Traction Syndrome
      • Visit Eye Health Professional
        • Eye Injection Costs and Rebates
      • Macular Disease
        • Anti-VEGF injections for macular disease
    • Research
      • Research Grants Program
        • Research Grants Awarded
        • Research Grant Recipients
        • Apply for the 2021 MDFA Research Grants Program
        • Research Grants panel
      • Support Research
      • Understanding Research
      • Latest Research
        • Research News
        • MDFA Research
        • Macular Diseases
        • Social Impact
      • Research Updates
        • Annual Research Update
        • Weekly Research Updates for Professionals
      • Research studies
    • Resources
      • Macula Month 2020
        • Order Macula Month resources
      • Order Publications and Resources
      • Find a Healthcare Provider
      • Audio and Video
        • Audio
        • See My World podcast
        • Patient Voices
        • Videos
      • Aged care resources
    • News & Events
      • Newsletters
        • Vision Voice Newsletters
        • Subscribe to Newsletters
        • Archive
      • News
        • 2020 news
        • 2019 News
        • 2018 News
        • 2017 News
        • 2016 News
        • Archived News
      • Events & Activities
        • Community Events
        • Education Sessions
        • Events Calendar
      • Media Centre
        • Media Releases
    • Foundation
      • Organisation
        • History
        • Objectives
        • Guiding Principles
        • Annual Reports
        • Whistleblower Policy
        • Financial Statements
      • People
        • Patron
        • State Patrons / Representatives
        • Ambassadors
        • Foundation Board
        • Committees
        • State Chairs
        • National Research Advisor
      • Our Work
        • Awareness
        • Education
        • Support Services
        • Research
        • Representation
      • Support Us
        • Donate
        • Bequests
        • Fundraise
        • Volunteer
        • Friends of the Foundation
        • Sponsors and Supporters
        • Professional Friends
      • Contact Us
  • Home
  • Macular Disease
  • Macular Degeneration
  • Treatment
  • Wet Macular Degeneration
Back

Macular Disease

  • Macular Degeneration
    • About Macular Degeneration
      • Check My Macula
        • Check My Macula sign up
    • What Happens?
    • Risk Factors
    • Prevention
      • Lifestyle
      • Nutrition
        • Nutrient Content of Foods
      • Supplements
    • Detection
      • Early Signs
      • Changes to Vision
      • Professional Testing
      • Amsler Grid
    • Diagnosis
    • Treatment
      • Early and Intermediate Macular Degeneration
      • Wet Macular Degeneration
      • Dry Macular Degeneration
    • Charles Bonnet Syndrome
    • Cataracts and Macular Degeneration
    • Frequently Asked Questions
    • How The Eye Works
  • Diabetic Retinopathy
    • About Diabetic Retinopathy
      • How the Eye Works
    • About Diabetes
      • Diabetes and the Eye
    • What Happens?
    • Risk Factors
    • Prevention
    • Detection
      • Testing
    • Diagnosis
    • Treatment
      • Diabetes Care Team
    • Frequently Asked Questions
  • Low Vision
    • Living with Low Vision
      • Causes
      • Impact
      • Challenges
      • Just Diagnosed
      • Maintaining Independence
        • Reading
        • Driving
        • Lifestyle
      • Low Vision Assessment
        • Visiting a Low Vision Service Provider
      • Coping Strategies
      • Depression
      • Charles Bonnet Syndrome
    • Carer and Family
      • Guide for Care
      • Becoming a Carer
      • Care Plan
      • Support Team
      • Effective Communication
      • Guiding
      • Caring for the Carer
      • Entitlements
      • Impact of Caring
    • Aids and Technology
      • Ten Step Action Plan
      • Living Aids
        • Lighting
        • Reading Aids
        • Optical Magnifiers
        • Spectacles
        • Organisation
        • Writing Aids
        • Talking Aids
        • Leisure
      • Mobility Aids
        • Guide Dogs
        • Canes
        • Electronic Mobility Aids
      • Technology
        • Mobile Phones
        • Television and Radio
        • Audio Technology
          • Computers and Software
          • Electronic Magnifiers
        • Subsidy Programs
      • Slips, Trips and Falls
        • Reducing Risk
          • Around the Home
          • In the Community
          • Your Health
            • Mobility and Strength
            • Medicines
          • Mobility Training
        • Falling
          • Why We Fall
          • Planning For Help
          • After A Fall
          • Fear of Falling
      • Legal blindness
    • Other Macular Diseases
      • Best Disease
      • Macular Hole
      • Macular Pucker
      • Macular Telangiectasia
      • Myopic Macular Degeneration
      • Retinal Detachment
      • Retinitis Pigmentosa
      • Retinal Vein Occlusion
      • Stargardt Disease
      • Central Serous Chorioretinopathy (CSC)
      • Vitreomacular Traction Syndrome
    • Visit Eye Health Professional
      • Eye Injection Costs and Rebates
    • Macular Disease
      • Anti-VEGF injections for macular disease

    Wet Macular Degeneration

    There are a number of medical treatments available for wet macular degeneration. These treatments do not cure the disease but aim to stabilise and maintain the best vision for as long as possible. In some people, treatment can improve vision. 

    A protein called Vascular Endothelial Growth Factor, or VEGF, is predominantly responsible for the leaking and growth of new blood vessels that result in rapid and severe vision loss, which if left untreated, becomes permanent. 

    To slow or stop this process, various drugs that block the protein, called anti-VEGFs, may be injected into the eye. 

    Clinical trials have shown that the use of anti-VEGF drugs maintains vision in the vast majority of wet macular degeneration patients. 

    About injections

    There are currently several anti-VEGF drugs used to treat wet age-related macular degeneration in Australia. The choice of the most appropriate drug should be discussed with your ophthalmologist.

    The treatment regimen for macular degeneration usually begins with monthly injections. Then, to control the disease, injections are typically continued on an indefinite basis. The interval between ongoing injections is determined by the ophthalmologist in consultation with the patient. 

    Regardless of which drug is used, the following advice about injection treatment applies:

    • Injection treatment is not a long procedure (although the overall procedure time may be a couple of hours or more) and usually occurs in the ophthalmologist’s rooms. Some patients may be treated in a day surgery facility
    • An anaesthetic is given before the injection, so very little discomfort should be experienced during the procedure
    • Appointments with the ophthalmologist should never be missed, even if there does not appear to be any problem with vision
    • Vision should continue to be monitored every day using an Amsler grid, one eye at a time. This self-monitoring is important for all injection schedules, regardless of injection frequency, and if injections have been discontinued.
    • Any sudden changes in vision should be reported to the ophthalmologist immediately as a matter of urgency, regardless of whether or not injections are being received – do not wait for the next appointment
    • Even if vision has stabilised or improved, treatment may still need to be continued
    • Treatment should not cease unless on the advice of the ophthalmologist
    • Injections are often required for an indefinite period to maintain vision
    • If there are any concerns regarding coping with injections or any difficulties post injection it is vitally important to raise these concerns with the ophthalmologist in the first instance, given the critical nature of the treatment.

    Read about the costs of injection treatment and rebates available.

    Lucentis®

    Ranibizumab, marketed in Australia as Lucentis, was the first anti-VEGF drug registered in Australia for the treatment of wet age-related macular degeneration.

    Lucentis was approved by the Therapeutic Goods Administration in 2007 and has Pharmaceutical Benefits Scheme listing. 

    Read current research about Lucentis.

    Eylea®

    Aflibercept, marketed in Australia as Eylea, is another anti-VEGF drug developed for the treatment of wet age-related macular degeneration. Eylea was approved by the Therapeutic Goods Administration in April 2012 and has Pharmaceutical Benefits Scheme listing. 

    Read current research about Eylea. 

    Avastin®

    Bevacizumab, marketed in Australia as Avastin, is an anti-VEGF drug, which was originally developed and registered to treat certain cancers. It is not registered by the Therapeutic Goods Administration for use in the eye. 

    For this reason, when treating patients for wet macular degeneration with Avastin, its use is called ‘off-label’. In Australia, Avastin is typically used for people who are not eligible to receive the approved drugs Lucentis or Eylea via the Pharmaceutical Benefits Scheme.

    Read current research about Avastin. 

    Laser 

    Photodynamic therapy

    Photodynamic Therapy (PDT) is a two-step process that combines a light-activated drug called Visudyne, with the light from a cool laser. The laser is directed on to the abnormal retinal area to seal and halt or slow the progression of abnormal retinal blood vessels. It is necessary to avoid sunlight for 24 to 48 hours after the drug has been infused.

    Unlike the results achieved from anti-VEGF drugs, patients having PDT normally continue to lose vision in the first six months of treatment. After this time, their condition generally stabilises so that the eye does not progress to severe vision loss. 

    PDT is now rarely used to treat ordinary age-related macular degeneration. Sometimes it is used in conjunction with an anti-VEGF drug for people with a type of macular degeneration called polypoidal choroidal vasculopathy. This is because the condition does not settle completely with anti-VEGF treatments alone.

    Laser photocoagulation

    Laser photocoagulation consists of a concentrated beam of high-energy thermal light, which is directed on to the retina to destroy and seal the leaky blood vessels. 

    The laser not only destroys the new leaking blood vessel but also destroys the retina adjacent to the new vessel. Therefore, it is primarily used for treating the small percentage of wet macular degeneration patients with new vessels that are not under the central vision. 

    There is a 50% recurrence rate following laser photocoagulation. This makes close follow up and monitoring with the ophthalmologist essential.

    Share this article
    Select Your Type?
     
     
     
    • Home
    • Macular Disease
    • Research
    • Resources
    • News & Events
    • Foundation

    Contact Us

    1800 111 709
    info@mdfoundation.com.au
    Suite 902, Level 9, 447 Kent Street, Sydney 2000

    Follow Us

    acnc_logo_reverse.png


    Helpline 1800 111 709

    Donate

    Macular Disease Foundation Australia ABN 52096255177
    • Privacy Policy
    • Site Map
    • Terms & Conditions
    • Disclaimer